Hepatitis C Market Report 2026

The hepatitis c market size has grown rapidly in recent years. It will grow from $75.72 billion in 2025 to $86.72 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to improved blood screening practices, expansion of antiviral drug availability, increased diagnosis rates, higher awareness of viral hepatitis, support from public health initiatives.

The hepatitis c market size is expected to see rapid growth in the next few years. It will grow to $153.67 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing elimination targets by health organizations, rising investments in hepatitis screening, growing adoption of simplified treatment protocols, expansion of telemedicine-based care, increasing access in emerging markets. Major trends in the forecast period include increasing adoption of direct-acting antivirals, rising focus on early screening programs, growing access to curative treatment regimens, expansion of public health awareness campaigns, enhanced focus on treatment adherence.

The increasing prevalence of viral infections is expected to drive the growth of the hepatitis C market in the coming years. Viral infections are caused by viruses that invade the body, and hepatitis C treatments work by eliminating the virus and restoring immune response in patients after viral clearance. For example, according to the Centers for Disease Control and Prevention, a US-based public health agency, the prevalence of Parvovirus B19, a seasonal respiratory viral infection, rose across all age groups from 3% during 2022-2024 to 10% in June 2024. The most significant increase was observed in children aged 5-9 years, where prevalence jumped from 15% during 2022-2024 to 40% by June 2024. Additionally, the proportion of pooled samples containing Parvovirus B19 DNA increased from 1.5% in December 2023 to 19.9% in June 2024. Therefore, rising viral infections are driving the hepatitis C market.

Key companies in the hepatitis C market are developing advanced products, such as dual antigen and antibody diagnostic tests, to improve the accuracy and efficiency of early detection and treatment. A dual antigen and antibody test identifies both hepatitis C virus (HCV) antigens and antibodies in a patient’s blood. For instance, in July 2023, Roche Diagnostics, a Switzerland-based company specializing in diagnostic tests, instruments, and digital solutions, launched Elecsys HCV Duo in India. This dual test allows simultaneous detection of HCV antigen and antibodies from a single plasma or serum sample. Its dual detection capability addresses the challenge of asymptomatic early infections, which often go undiagnosed due to the absence of antibodies in the initial stages. By identifying active infections sooner, Elecsys HCV Duo enables healthcare providers to initiate treatment more quickly, potentially reducing disease progression and transmission.

In July 2025, Thailand’s Government Pharmaceutical Organization (GPO) partnered with DNDi and Pharco to register an effective and affordable hepatitis C treatment. The collaboration aims to improve access to high-quality antiviral therapies and broaden their availability, enhancing patient outcomes in hepatitis C management while promoting innovation and growth in the global infectious disease treatment market. DNDi is an international non-profit organization focused on developing treatments for neglected diseases, and Pharco is an Egyptian pharmaceutical company specializing in the production and distribution of innovative medicines.

Major companies operating in the hepatitis c market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Lupin Limited, Cadila Healthcare Ltd., Biocon Limited.

North America was the largest region in the hepatitis C market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis c market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis c market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hepatitis C market by increasing costs of imported antiviral drugs, diagnostic kits, and pharmaceutical intermediates. Healthcare systems in North America and Europe are most affected due to reliance on branded therapies, while Asia-Pacific faces cost pressure on generic drug production and export. These tariffs are raising treatment expenses and affecting large-scale elimination programs. However, they are also encouraging domestic drug manufacturing, regional formulation capabilities, and expanded production of affordable antiviral therapies.

The hepatitis c market research report is one of a series of new reports that provides hepatitis c market statistics, including hepatitis c industry global market size, regional shares, competitors with a hepatitis c market share, detailed hepatitis c market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis c industry. This hepatitis c market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatitis C is a viral infection that primarily targets the liver, causing inflammation, liver damage, and, if left untreated, potentially leading to cirrhosis or liver cancer. The virus spreads through contact with infected blood and is managed using antiviral medications designed to eliminate the virus from the bloodstream.

The main types of hepatitis C include chronic hepatitis C, acute hepatitis C, and others. Chronic hepatitis C is a long-lasting infection that occurs when the body is unable to clear the virus. Treatment options include antiviral drugs, vaccines, immune-modulating medications, surgery, and other therapies. Diagnosis typically involves liver biopsy, blood tests, imaging studies, and additional methods. These treatments and diagnostic tools are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End-users of these products and services include hospitals, clinics, ambulatory surgical centers, diagnostic laboratories, research institutes, and homecare settings.

The hepatitis C market consists of revenues earned by entities by providing shunt procedures, hepatic resection, and biopsies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C market also includes sales of ledipasvir and sofosbuvir, non-structural protein 5B (NS5B) polymerase inhibitors, non-structural protein 5A (NS5A) replication complex inhibitors, and elbasvir and grazoprevir drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.